Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: results from the open-label extension of PARADIGM-HF
Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac